Capricor investor calls for change as company awaits decision on Duchenne candidate
An investor pushes for strategic changes at Capricor Therapeutics as the company awaits an FDA decision on its Duchenne muscular dystrophy therapy candidate.
Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a cell therapy company headquartered in Beverly Hills, California, USA.
Company Info
Upcoming Milestones & Key Dates
2026-08-11
Earnings
Q2 2026 earnings
2026-09-30
Regulatory
FDA AdComm for deramiocel (DMD cardiomyopathy)
2026-12-15
Regulatory
PDUFA target for deramiocel
Clinical Development Pipeline
Deramiocel (CAP-1002)
Target: Cardiosphere-derived cellsCAP-1002
Target: Cardiosphere-derived cellsStealthX
Target: Engineered exosomeRecent News
Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data
Endpoints News reports Capricor Therapeutics plans to ask FDA to review additional data for its Duchenne muscular dystrophy therapy.
Capricor soars on plan to amend DMD filing after adcomm setback
Capricor has bounced back from a bruising FDA advisory committee meeting by securing a green light to file an amendment to its approval application.
Capricor soars on potential FDA review extension, filing amendments
Capricor Therapeutics' CEO Linda Marbán believes the FDA is willing to work with the biotech as the Aug. 22 deadline approaches for its Duchenne muscular dystrophy cell therapy deramiocel.
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting. Reported by BioSpace on 2026-07-29.
Updated: FDA adcomm votes down Capricor's DMD therapy over efficacy
Updated: FDA adcomm votes down Capricor's DMD therapy over efficacy. Reported by Endpoints News on 2026-07-29.
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy. Reported by BioSpace on 2026-07-27.
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy
Capricor thrown for another loop as FDA sets adcomm for DMD cardiomyopathy therapy.
Leadership Team
Linda Marbán
CEO & Co-founder
AJ Bergmann
CFO
Karen B. Goldschmidt, MD
VP, Clinical Operations